Literature DB >> 6954329

Arachidonic acid metabolites, hypertension and arteriosclerosis.

P C Weber, W Siess, B Scherer, E Held, H Witzgall, R Lorenz.   

Abstract

The level of arterial blood pressure is set by complete interactions of several mechanisms which influence both blood flow in and resistance of the vascular system. An imbalance favouring elevation of vascular resistance or extracellular volume will result in hypertension. Such alterations may include increased activity of the sympathetic nervous system, of the renin-angiotensin system, or excessive secretion of mineralocorticoids. Of equal importance may be a reduced activity of blood pressure-lowering factors such as prostaglandins and the kallikrein-kinin system. This paper describes the possible significance of prostaglandins in the pathophysiology of hypertension and in degenerative vascular disease, based on their involvement in the control of vascular resistance, renal regulation of extracellular volume and platelet-vessel wall interactions. An abnormality in the biosyn-thesis of certain prostaglandin endoperoxide metabolites may lead to hypertension even without an increase in the activity of the classic blood-pressure-elevating systems. The contribution of prostaglandins for the development of hypertension and degenerative vascular disease may be based on an inherent abnormality of the prostaglandin system, as well as on the effects of major risk factors such as dietary intake of sodium and fat on prostaglandin synthesis. Specific blockade or stimulation of distinct biosynthetic pathways leading to antagonistically acting prostaglandins and nutritional manipulation of precursor fatty acids should lead to a better understanding of the pathomechanisms involved and may offer new strategies for therapy or prevention of these cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6954329     DOI: 10.1007/bf01756093

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  87 in total

Review 1.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

Authors:  S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

2.  Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease.

Authors:  J W Haerem
Journal:  Atherosclerosis       Date:  1972 Mar-Apr       Impact factor: 5.162

3.  A role of renal cortical prostaglandins in the control of glomerular filtration rate in rat kidneys.

Authors:  J Schnermann; P C Weber
Journal:  Adv Prostaglandin Thromboxane Res       Date:  1980

4.  Pediatric aspects of atherosclerosis and hypertension.

Authors:  J Lee; R M Lauer
Journal:  Pediatr Clin North Am       Date:  1978-11       Impact factor: 3.278

5.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

6.  Interaction between furosemide-induced renal vasodilation and the prostaglandin system.

Authors:  J G Gerber; A S Nies
Journal:  Prostaglandins Med       Date:  1981-02

7.  Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension.

Authors:  J Webster; C T Dollery; C N Hensby
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

8.  Angiotensin-II-stimulated release of thromboxane A2 and prostacyclin (PGI2) in isolated, perfused kidneys of spontaneously hypertensive rats.

Authors:  Y Shibouta; Y Inada; Z Terashita; K Nishikawa; S Kikuchi; K Shimamoto
Journal:  Biochem Pharmacol       Date:  1979-12-15       Impact factor: 5.858

9.  Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet.

Authors:  W Siess; P Roth; B Scherer; I Kurzmann; B Böhlig; P C Weber
Journal:  Lancet       Date:  1980-03-01       Impact factor: 79.321

10.  Prostacyclin mediates the potentiated hypotensive effect of bradykinin following captopril treatment.

Authors:  K M Mullane; S Moncada
Journal:  Eur J Pharmacol       Date:  1980-09-05       Impact factor: 4.432

View more
  3 in total

1.  Inhibition of cyclooxygenase attenuates baroreceptor function and increases the pressor response to norepinephrine in man.

Authors:  B Weisser; G Kayser; S Wagner; B O Göbel; H Vetter; R Düsing
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Maternal and fetal prolactin in pregnancy-induced hypertension.

Authors:  M G Marlettini; A Cassani; A M Morselli-Labate; S Crippa; A Contarini; R Miniero; L Platè; C Orlandi
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

3.  Metabolomic and lipidomic profile in men with obstructive sleep apnoea: implications for diagnosis and biomarkers of cardiovascular risk.

Authors:  Adriana Lebkuchen; Valdemir M Carvalho; Gabriela Venturini; Jéssica S Salgueiro; Lunara S Freitas; Alessandra Dellavance; Franco C Martins; Geraldo Lorenzi-Filho; Karina H M Cardozo; Luciano F Drager
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.